NCT03267485

Brief Summary

The aim of the present study is to detect the expression of TET 1 gene in patients with acute leukemia and its correlation with clinical and pathological criteria of the patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2017

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 29, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 30, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

November 1, 2017

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

August 30, 2017

Status Verified

August 1, 2017

Enrollment Period

1 year

First QC Date

August 29, 2017

Last Update Submit

August 29, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • expression of TET1 gene in acute leukemia

    role of TET1 gene expression in leukemogenesis

    baseline

Interventions

Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

acute leukemia patients at diagnosis or relapse .

You may qualify if:

  • \- sample from acute leukemia patients at diagnosis or relapse . healthy subjects as control .

You may not qualify if:

  • Patients having any other haematological malignancies.
  • Patient with acute leukemia in remission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Jain A, Varma S, Garg R, Malhotra P. Unilateral Gynaecomastia in a Young Man with Chronic Myeloid Leukemia. Indian J Hematol Blood Transfus. 2017 Sep;33(3):448-450. doi: 10.1007/s12288-016-0762-z. Epub 2016 Dec 19.

    PMID: 28824259BACKGROUND
  • Lee BS, Jan YD, Huang GS, Huang CH, Chou HY, Wang JS, Tseng WY. Effect of dentin bonding agent diffusing through dentin slices on the reactive oxygen species production and apoptosis of pulpal cells. J Formos Med Assoc. 2015 Apr;114(4):339-46. doi: 10.1016/j.jfma.2012.12.009. Epub 2013 Feb 13.

    PMID: 25839767BACKGROUND

MeSH Terms

Interventions

Real-Time Polymerase Chain Reaction

Intervention Hierarchy (Ancestors)

Polymerase Chain ReactionNucleic Acid Amplification TechniquesGenetic TechniquesInvestigative Techniques

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor of clinical pathology department South Egypt Cancer Institute

Study Record Dates

First Submitted

August 29, 2017

First Posted

August 30, 2017

Study Start

November 1, 2017

Primary Completion

November 1, 2018

Study Completion

December 1, 2018

Last Updated

August 30, 2017

Record last verified: 2017-08